Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

References

• HIV/AIDS Italian Expert PanelLinee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-12016 Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2545_allegato.pdf Accessed November 22, 2016
   Google Scholar
• The Medicines Utilisation Monitoring CentreNational Report on Medicines Use in ItalyRomeItalian Medicines Agency2015 Available from: http://www.agenziafarmaco.gov.it/sites/default/files/Rap-porto_OsMed_2015__AIFA.pdfAccessed May 19, 2017
   Google Scholar
• European Medicines AgencyEPAR Summary for the Public – Tivicay Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002753/WC500160681.pdfAccessed May 19, 2017
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsDepartment of Health and Human Services Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdfAccessed May 19, 2017
   Google Scholar
• ClotetBFeinbergJvan LunzenJING114915 Study TeamOnce-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyLancet201438399362222223124698485
   PubMed Web of Science ®Google Scholar
• MolinaJMClotetBvan LunzenJOnce-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGOJ Int AIDS Soc2014174 suppl 31949025393999
   PubMed Web of Science ®Google Scholar
• WalmsleySLAntelaAClumeckNSINGLE InvestigatorsDolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionN Engl J Med2013369191807181824195548
   PubMed Web of Science ®Google Scholar
• RaffiFRachlisAStellbrinkHJSPRING-2 Study GroupOnce-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyLancet2013381986873574323306000
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanEExtended SPRING-2 Study GroupOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialLancet Infect Dis2013131192793524074642
   PubMed Web of Science ®Google Scholar
• CahnPPozniakALMingroneHExtended SAILING Study TeamDolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyLancet2013382989370070823830355
   PubMed Web of Science ®Google Scholar
• Directorate General for Health of Lombardy RegionD.d.g. 22 December 2014 – n. 12515 – Approvazione del documento avente ad oggetto “Percorso diagnostico terapeutico (PDT) del paziente affetto da malattia HIV/AIDS – anno 2105” Available from: http://omceomi.it/docs/default-source/leggi-e-norme/percorso-diagnostico-terapeutico-paziente-affetto-da-malattia-hiv-aids-anno-2015-burl-30-12-2014.pdf?sfvrsn=0Accessed May 15, 2015
   Google Scholar
• Regione LazioDecreto del Commissario ad acta n. U00002 del 13 Gennaio 2014 – Allegato A “Percorso Diagnostico Terapeutico (POT) Regionale sulla Terapia Antiretrovirale” Available from: http://www.regione.lazio.it/binary/rl_sanita/tbl_normativa/Decr_U00002_13_1_13_aggiornamento_terapia_HIV.pdfAccessed November 24, 2015
   Google Scholar
• Decreto del Segretario della Segreteria Regionale per la Sanità n. 148 del 02 Dicembre 2013 – Allegato A “Percorso Diagnostico Terapeutico Assistenziale (PDTA) del paziente adulto affetto da infezione da HIV/AIDS nella Regione Veneto” Available from: http://bur.regione.veneto.it/BurvServices/Pubblica/DettaglioDecreto.aspx?id=263808Accessed November 24, 2015
   Google Scholar
• DespiégelNAngerDMartinMCost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in CanadaInfect Dis Ther20154333735326099626
   PubMedGoogle Scholar
• StellbrinkHJReynesJLazzarinADolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyAIDS201327111771177823807273
   PubMed Web of Science ®Google Scholar
• RockstrohJKDeJesusESaagMLong-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naïve HIV-1 infected patients: final 5-year double-blind results from STARTMRKPresented at: XIX International AIDS ConferenceJuly 22–27; 2012Washington, DC
   Google Scholar
• D’ArminioMASabinCAPhillipsAThe changing incidence of AIDS events in patients receiving highly active antiretroviral therapyArch Intern Med200516541642315738371
   PubMed Web of Science ®Google Scholar
• Italian Health Economics Association (AIES)Proposta di Linee-Guida per la valutazione economica degli interventi sanitariPolitiche Sanitarie20091029199
   Google Scholar
• Italian National Institute of HealthAIDS Operative CentreNotiziario dell’Istituto Superiore di Sanità2016299 Suppl 1 Available from: http://www.iss.it/binary/ccoa/cont/dic_2015.pdfAccessed May 19, 2017
   Google Scholar
• HIV/AIDS Italian expert panelLinee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-12014 Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2261_allegato.pdfAccessed December 18, 2014
   Google Scholar
• MauskopfJBroganAJTalbirdSEMartinSCost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infectionAIDS201226335536422089378
   PubMed Web of Science ®Google Scholar
• Italian Statistics National Institute [homepage on the Internet]I.Stat Database Available from: http://dati.istat.it/Index.aspxAccessed May 19, 2017
   Google Scholar
• LewdenCCheneGMorlatPAgence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study GroupAgence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study GroupHIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general populationJ Acquir Immune Defic Syndr2007461727717621240
   PubMed Web of Science ®Google Scholar
• Regione del Veneto [webpage on the Internet]Percorso Diagnostico Terapeutico Assistenziale (PDTA) del paziente adulto affetto da infezione da HIV/AIDS nella Regione Veneto. Allegato A al Decreto n. 148 del 2 Dicembre 2013 Available from: http://bur.regione.veneto.it/BurvServices/Pubblica/DettaglioDecreto.aspx?id=263808Accessed May 19, 2017
   Google Scholar
• Regione del VenetoPercorso Diagnostico Terapeutico Assistenziale (PDTA) del paziente adulto affetto da infezione da HIV/AIDS nella Regione Veneto – aggiornamento a febbraio 2016. Allegato A al Decreto n. 55 del 8 Giugno 2016 Available from: https://www.regione.veneto.it/c/document_library/get_file?uuid=3beb4023-6e19-4d71-a73e-48-a4e6161d3d&groupId=10793Accessed May 19, 2017
   Google Scholar
• Regione CalabriaPercorso Diagnostico Terapeutico Assistenziale (PDTA) regionale del Paziente affetto da malattia da HIV/AIDS Available from: http://www.regione.calabria.it/sanita/allegati/dpgr_2012/allegato_1_dpgr_198_del_20_dicembre_2012.pdfAccessed May 19, 2017
   Google Scholar
• PialouxGMarcelinAGDespiégelNCost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in FrancePLoS One20151012e014588526714188
   PubMed Web of Science ®Google Scholar
• PengSTafazzoliADormanERosenblattLVillasis-KeeverASorensenSCost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United StatesJ Int AIDS Soc2014174 suppl 31960525394109
   PubMed Web of Science ®Google Scholar
• KaufTLRoskellNShearerAA predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapyValue Health20081171144115318494750
   PubMed Web of Science ®Google Scholar
• SimpsonKNLuoMPChumneyECKingMSBrunSCost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart diseaseClin Drug Investig20072716774
   PubMed Web of Science ®Google Scholar
• PaltielADScharfsteinJASeageGR3rdA Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infectionMed Decis Making1998182 supplS93S1059566470
   PubMed Web of Science ®Google Scholar
• SchackmanBRGoldieSJFreedbergKALosinaEBrazierJWeinsteinMCComparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDSMed Decis Making2002221273811833663
   PubMed Web of Science ®Google Scholar
• RizzardiniGRestelliUBonfantiPCost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?Clinicoecon Outcomes Res2012424525222973114
   PubMedGoogle Scholar
• RaitanoM“The Impact of Death-Related Costs on Health-Care Expenditure: A Survey”, ENEPRI Research Report No. 1722006
   Google Scholar
• SimpsonKNLuoMPChumneyESunEBrunSAshrafTCost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infectionHIV Clin Trials20045529430415562370
   PubMed Web of Science ®Google Scholar